WO2004000323A1 - セフェム化合物の注射用医薬組成物 - Google Patents
セフェム化合物の注射用医薬組成物 Download PDFInfo
- Publication number
- WO2004000323A1 WO2004000323A1 PCT/JP2003/007610 JP0307610W WO2004000323A1 WO 2004000323 A1 WO2004000323 A1 WO 2004000323A1 JP 0307610 W JP0307610 W JP 0307610W WO 2004000323 A1 WO2004000323 A1 WO 2004000323A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- component
- composition according
- compound
- turbidity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a pharmaceutical composition for injection of a cefm compound.
- sugars, sugar alcohols, inorganic salts (eg, NaCl) and the like are known to be effective as stabilizers for injections of cefm antibiotics.
- JP-A-57-11909 and JP-A-60-45514 are reported as freeze-dried preparations of oxacefum.
- JP-A-63-17827 and JP-A-4-159030 have been reported.
- WO 00/32606 also includes a compound represented by the formula:
- compound (I) (Hereinafter referred to as compound (I)) and salts thereof.
- the sulfate crystals are described in PCT7JP 02/03902 and also published at ICCAC (Chicago, December 16, 2001).
- Compound (I) is a wide-ranging cefm compound that is also effective against methicillin-resistant Staphylococcus aureus (MRSA), and is particularly expected to be developed as an injection. Therefore, it is desired to provide a compound (I) having a high storage stability and high practicality, which is free from turbidity during dissolution, and particularly a lyophilized preparation and a spray-dried preparation. Disclosure of the invention
- the present inventors have obtained the following findings as a result of various analyzes of the physical properties of compound (I) in order to develop compound (I) as an injection.
- aqueous solution of a sulfate crystal of compound (I) When an aqueous solution of a sulfate crystal of compound (I) is freeze-dried or spray-dried, it may be converted to amorphous. 2) The amorphous is not high in storage stability. Also, it is easily insolubilized and may become turbid when redissolved in water. 3) Since the sulfate of compound (I) has a highly acidic pH of 2.3 according to the Japanese Pharmacopoeia General Test, it can be injected into a living body at a physiological pH that can be injected, that is, weakly acidic to neutral. It is necessary to adjust near.
- a pharmaceutical composition for injection characterized by containing the following components (A) and (B):
- component (B) is one or more additives selected from the group consisting of glucose, maltose, mannitol and NaC1.
- component (B) is one or more additives selected from the group consisting of glucose, maltose, mannitol and NaC1.
- a method for producing a pharmaceutical composition for injection comprising a step of dehydrating an aqueous solution containing the following components (A) and (B):
- additives selected from the group consisting of monosaccharides, disaccharides, sugar alcohols, and inorganic salts.
- the aqueous solution contains the compound (I) as the component (A), a sulfate thereof or a solvate thereof, NaCl as the component (B), and NaOH or a basic amino acid as the component (C).
- (26) A freeze-dried or spray-dried preparation of compound (I), obtained by the production method according to any one of the above (23) to (25).
- the component (A), which is the main drug of the pharmaceutical composition for injection (hereinafter, also referred to as the present composition) of the present invention, comprises:
- the compound (I) described in WO 00/32606, a pharmaceutically acceptable salt thereof, or a solvate thereof is useful as an antibacterial agent.
- Examples of pharmaceutically acceptable salts include salts formed with inorganic bases, ammonia, organic bases, inorganic acids, organic acids, basic amino acids, halogen ions, and the like, or internal salts.
- the inorganic base include alkali metals (Na, K, etc.), alkaline earth metals (Mg, etc.)
- examples of the organic base include proforce, 2-phenylethylbenzylamine, dibenzylethylenediamine, Ethanolamine, diethanolamine, trishydroxymethylaminomethane, polyhydroxyalkylamine, N-methyldarcosamine and the like are exemplified.
- Examples of the inorganic acid include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like.
- Examples of the organic acid include p-toluenesulfonic acid, methanesulfonic acid, formic acid, trifluoroacetic acid, and maleic acid.
- Examples of the basic amino acid include lysine, L-arginine, ordinine, histidine and the like.
- solvates include hydrates (eg, monohydrate, dihydrate, trihydrate, tetrahydrate, pentahydrate, hexahydrate, heptahydrate) and alcohol solvates Things are illustrated.
- Component (A) is preferably a sulfate of compound (I) (eg, 0.5 sulfate, monosulfate) or a hydrate thereof. Particularly preferred is monosulfate or a hydrate thereof (eg, 1, 2, 3, 4, pentahydrate, etc.). Crystals of the monosulfate of compound (I) are more advantageous in terms of storage stability. However, the crystals may be converted to amorphous in a formulation step such as freeze-drying or spray-drying, and are degraded during the formulation step and subsequent storage, and a decrease in titer is observed. At this time, a decomposed product derived from the side chain at the 3-position and a compound of the compound (I) are mixed.
- a sulfate of compound (I) eg, 0.5 sulfate, monosulfate
- a hydrate thereof eg, 1, 2, 3, 4, pentahydrate, etc.
- Component (B) is blended as a stabilizer to suppress the decomposition of component (A) during the formulation process and storage. It also has the effect of suppressing or reducing turbidity when the component (A) is dissolved in an infusion solution for injection (eg, physiological saline, pudose solution) or the like. It is presumed that the effect of preventing turbidity is caused by suppressing the formation of the polymer (eg, dimer, trimer) of component (A).
- Component (B) is one or more additives selected from the group consisting of monosaccharides, disaccharides, sugar alcohols and inorganic salts.
- Examples of the monosaccharide include glucose, mannose, galactose, and fructose, and glucose is preferred.
- disaccharide examples include maltose, sucrose, lactose, fructose, trehalose, xylitol and the like, and preferably maltose.
- sugar alcohol examples include D-mannitol, sorbitol, glycerol, inositol and the like, and preferably, D-mannitol.
- NaC l As the inorganic salt, NaC l, but KC 1, CaC l 2, M g C 1 ⁇ , and the like, a preferred lay NaC l.
- Component (B) is preferably an inorganic salt, especially NaCl.
- the content of the component (B) is usually about 0.1 to 5 molar equivalents, preferably about 0.5 to 3 molar equivalents, more preferably about 1 to 3 molar equivalents, more preferably about 1.5 to 3 molar equivalents with respect to the component (A). ⁇ 2.5 molar equivalents.
- NaC1 sodium chloride
- the content of the component (B) is usually about 0.1 to 5 molar equivalents, preferably about 0.5 to 3 molar equivalents, more preferably about 1 to 3 molar equivalents, more preferably about 1.5 to 3 molar equivalents with respect to the component (A).
- ⁇ 2.5 molar equivalents In particular, when NaC1 is used, the higher the content, the more the component (A) is stabilized, and the turbidity during dissolution in water is suppressed. In particular, when 2 molar equivalents of NaC1 content are used, turbidity is suppressed to about 10% to 2% when 1 molar equivalent is used.
- the effect of suppressing turbidity reaches a nearly constant level when the NaC 1 content is 2 molar equivalents, and when added more than that, some disintegration may be observed in the appearance of the lyophilized product .
- the content of NaCl is about 1 to 3 molar equivalents, more preferably about 1.5 to 2.5 molar equivalents, and particularly about 2 molar equivalents, relative to component (A).
- the preferable content range of the component (B) is pH 3 to 7, preferably pH 4 to 7, when the composition is dissolved in water so as to have a concentration of 100 to 200 mg (potency) / g as the component (A).
- composition of the present invention is dissolved in physiological saline so as to have a concentration of 5 mg (titer) / g as component (A), pH 3 to 7, preferably pH 3.5 to 6, particularly preferably 4 to 6 This is suitable when the adjustment is made so that
- the present composition may contain (C) a pH adjuster.
- a pH adjuster various agents that can be adjusted to a physiological pH (eg, pH 3 to 7) to use the present composition as an injection can be used.
- hydroxides of alkali metals eg, NaOH, KOH
- Al force Li metal carbonate e.g. Na 2 CO NaHCO 3
- basic amino acids e.g. lysine, L- arginine, ol two Chin, histidine
- the content of the pH adjuster is usually such that the pharmaceutical composition of the present invention becomes pH 3 to 7 when dissolved in an infusion solution for injection.
- the pH is adjusted to be 5 to 7, preferably pH 6 to 7 near neutrality. I can do it.
- this composition is dissolved in physiological saline so as to have a concentration of 5 mg (titer) / g as the component (A)
- the pH becomes 3 to 7, preferably 3.5 to 6, and particularly preferably 4 to 6.
- the content of NaOH is about 1.0 to 1.5 molar equivalents, preferably about 1.1 to 1.3 molar equivalents, relative to component (A).
- the amount of L-arginine is about 1.0 to 1.5 molar equivalents, preferably about 1.1 to 1.2 molar equivalents. Since the acid addition salt of compound (I) is strongly acidic as a single agent (eg, pH 2.3 with monosulfate), it needs to be adjusted to the above physiological pH when used as an injection. The mere addition of the (C) pH regulator lowers the stability and causes significant turbidity upon re-dissolution. However, these inconveniences can be prevented by blending the component (B).
- the present composition preferably contains the above components (A), (B) and (C). In this case, preferably (B) is NaCl.
- the content of NaCl is 1 to 3 molar equivalents, preferably about 1.5 to 2.5 molar equivalents, relative to component (A). More preferably, when the composition is dissolved in an infusion solution for injection, the content of the PH regulator is the above-mentioned physiological pH, for example, 100 to 20 Omg (potency) of the composition as the component (A).
- the pH is set to be 5 to 7, preferably 6 to 7 when dissolved in water, and particularly preferred pH adjusters are NaOH and L-arginine.
- the shape of the present composition is not necessarily limited, but is preferably a powder preparation such as a freeze-dried preparation or a spray-dried S agent, and can be preferably filled in a vial. More preferably, they are sterile and pyrogen-free preparations.
- the present composition has improved stability during the formulation step or subsequent storage as described below, and suppresses or reduces turbidity when dissolved in an infusion solution for injection.
- the residual ratio of the component (A) after storage at 50 ° C. for one week in a vial or the like may be 70% or more, preferably 75% or more, more preferably 80% or more before storage.
- the composition is turbid when the component (A) is dissolved in an infusion solution for injection (preferably physiological saline) to a concentration of, for example, 5 mg (titer) / g after storage at 50 ° C for 1 week in a vial.
- the degree can be 1.0 D or less, preferably 0.5 or less, more preferably 0.1 or less, even more preferably 0.05 or less, particularly preferably 0.02 or 0.01 or less at 600 nm: 600 nm.
- the composition comprises (A) a sulfate of compound (I) or a solvate thereof, (B) NaC 1, and (C) a pH adjuster (eg, NaOH).
- the content of C1 is about 1 to 3 molar equivalents with respect to the component (A)
- the content of the pH regulator is about 1.0 to 1.5 molar equivalents
- the cells are stored at 50 ° C for one week.
- the residual ratio of the component (A) is 70% or more, preferably 75% or more, more preferably 80% or more before storage, and the component (A) is used for injection so that 5 mg (titer) Zg is obtained.
- the turbidity when dissolved in an infusion is 0! D .: 600 nm is 1.0 or less, preferably 0.5 or less, more preferably 0.1 or less, further preferably 0.05 or less, particularly preferably 0.02 or 0.01 or less.
- the present composition is produced by mixing the above components (A) and (B), and if desired, the component (C). More preferably, it is obtained by preparing an aqueous solution containing the components (A) and (B) and, if desired, the component (C), and subjecting it to a dewatering step such as freeze drying or spray drying.
- a dewatering step such as freeze drying or spray drying.
- the form of the compound (I) is not particularly problematic, and may take various forms depending on the types and contents of the components (B) and (C). For example, it may be in any form such as a free form, an acid addition salt (eg, sulfate), an alkali metal salt, an amino acid addition salt, or a mixture thereof.
- compound (I) is released as a free form when redissolved in water, the desired injection can be obtained.
- compounding component (C) prepare a freeze-dried or spray-dried product containing components (A) and (B), and then prepare (C) as a powder in two layers or as an attached solution. Combinations are possible, and such forms are also within the scope of the present invention.
- aqueous solution having a predetermined concentration containing components (A) to (C) (eg, component (A) 100 to 200 mg / g in titer) and pH (3 to 7, preferably 5 to 6), filtration is performed. After that, the mixture is frozen at a temperature of from 20 to 150 ° C, preferably from 130 to 140 ° C, for several hours, preferably for 2 to 5 hours (freezing). Next, for several hours to several tens of hours, preferably 20 to 30 hours at a vacuum of 1 to 20 ° C., preferably 0 to 5 and 2 to 50 Pa, preferably 5 to 20 Pa. Dry (—subsequent drying).
- the temperature of the spray dryer is set at In 150 to 200 ° C, preferably 180 to 200 ° C, Out 90 to 140 ° C, preferably 120 to 130 ° C.
- component (A) It is hard to cause thermal decomposition and is preferable for reducing the water content.
- the collection bottle should be heated (35-90 ° C, preferably 50-70 ° C) to prevent re-absorption. It is preferable to keep it. After spray drying, the obtained powder is divided into vials.
- the components (A) and (B) are spray-dried according to the above, the obtained powder is divided into vials, and the component (C) is filled.
- the present invention also provides a pharmaceutical composition for injection obtained by the above-mentioned production method (eg, freeze-dried preparation, spray-dried preparation, injection using the same).
- a pharmaceutical composition for injection obtained by the above-mentioned production method (eg, freeze-dried preparation, spray-dried preparation, injection using the same).
- the pharmaceutical composition for injection of the present invention is preferably used as an antibacterial agent in the form of intravenous drip injection or intramuscular injection by dissolving it in an infusion solution for injection (eg, physiological saline, budou sugar solution).
- an infusion solution for injection eg, physiological saline, budou sugar solution.
- the component (A) is the compound (I) as a compound (I) in an amount of about l-20 mg (titer) / g, preferably about 5-10 mg (titer) / g.
- the present invention further provides a method for producing an antibacterial agent and a method for preventing and treating various infectious bacteria, characterized by using the present composition.
- compound (I) may be administered to a human in an amount of about 0.1 to 10 Omg / kg / day, preferably about 0.5 to 5 Omg / kg / day, and optionally 2 to 4 Omg / kg / day.
- the administration may be carried out in divided doses.
- compound S hydrated monosulfate crystals (2 or 3 hydrate) of the compound (I) were used (hereinafter, defined as compound S).
- the amount of the additive is the amount added to compound S.
- the turbidity was evaluated by the OD (absorbance) 60 Onm value when the freeze-dried preparation or the spray-dried preparation was redissolved in physiological saline so as to have a compound S concentration of 5 mg (titer) / mg.
- the pH of the solution was in the range of pH 3 to 4 in each case.
- a freeze-dried preparation was prepared according to Test Example 1, and the storage stability and turbidity upon re-dissolution were examined. Since compound S has a strongly acidic pH value of 2.3 according to the Japanese Pharmacopoeia General Test Method, it needs to be adjusted to a physiological pH that can be administered intravenously when administered to a living body. Therefore, the pH was adjusted to be suitable for use as an injection by using an aqueous sodium hydroxide solution.
- a lyophilized preparation was prepared according to Test Example 1 and examined by changing the NaC1 content. (Table 3)
- a lyophilized preparation was prepared according to Test Example 1, and a comparison was made between preparations in which NaCl was added at 2.0 molar equivalents and 3.0 molar equivalents relative to compound S.
- a freeze-dried preparation was prepared according to Test Example 1, and the effect of pH was examined.
- a freeze-dried preparation was prepared according to Test Example 1, and the effect of adding maltose was examined ( (Table 6)
- the powder was subdivided into 20 mL vials (BVK-20 vial) in a low-humidity nitrogen environment (in a dry box) so as to obtain 10 Omg (titer) and accelerated at 50 ° C (1 Weeks) to examine the storage stability and turbidity during reconstitution.
- a spray-dried preparation was prepared according to Test Example 8, and the storage stability and turbidity upon re-dissolution were examined. Since compound S has a strongly acidic pH value of 2.3 according to the Japanese Pharmacopoeia General Test Method, it needs to be adjusted to a physiological pH that can be administered intravenously when administered to a living body. Therefore, the formulation containing 20% maltose, which had a high turbidity and stabilizing effect in Test Example 8, was adjusted to a pH suitable for use as an injection using an aqueous sodium hydroxide solution. .
- a spray-dried preparation was prepared according to Test Example 8, and the storage stability and the turbidity upon re-dissolution were examined by changing the NaC1 content.
- a spray-dried preparation was prepared according to Test Example 8, and a comparison was made between L-arginine as a pH adjuster and the pH adjusted during liquid preparation, and a two-layer filled pH adjuster.
- Test Example 8 A spray-dried preparation was prepared according to Test Example 8, and a comparison was made between L-arginine as a pH adjuster and the pH adjusted during liquid preparation, and a two-layer filled pH adjuster.
- Table 12 Additive storage conditions
- the present invention provides an injectable pharmaceutical composition having high storage stability for compound (I) and high practicability without turbidity upon reconstitution.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003241675A AU2003241675A1 (en) | 2002-06-21 | 2003-06-16 | Medicinal cephem compound composition for injection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002181428 | 2002-06-21 | ||
JP2002-181428 | 2002-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004000323A1 true WO2004000323A1 (ja) | 2003-12-31 |
Family
ID=29996628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/007610 WO2004000323A1 (ja) | 2002-06-21 | 2003-06-16 | セフェム化合物の注射用医薬組成物 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003241675A1 (ja) |
WO (1) | WO2004000323A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1656930A1 (en) * | 2004-11-10 | 2006-05-17 | Basilea Pharmaceutica AG | Stabilized freeze-dried formulation for cephalosporin derivatives |
EP2257159A2 (en) * | 2008-03-04 | 2010-12-08 | Elan Pharma International Limited | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4616083A (en) * | 1983-08-22 | 1986-10-07 | Shionogi & Co., Ltd. | Stable antibacterial lyophilizates |
US4822785A (en) * | 1986-07-10 | 1989-04-18 | Eisai Co., Ltd. | Cephalosporin injection |
JPH03264531A (ja) * | 1990-03-13 | 1991-11-25 | Mochida Pharmaceut Co Ltd | セファロスポリン凍結乾燥製剤 |
JPH0459730A (ja) * | 1990-06-26 | 1992-02-26 | Dai Ichi Seiyaku Co Ltd | セフェム系抗生物質含有凍結乾燥製剤 |
EP1134222A1 (en) * | 1998-11-27 | 2001-09-19 | Shionogi & Co., Ltd. | IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM |
WO2002088147A1 (fr) * | 2001-04-23 | 2002-11-07 | Shionogi & Co., Ltd. | Sulfate d'un compose cepheme |
-
2003
- 2003-06-16 WO PCT/JP2003/007610 patent/WO2004000323A1/ja not_active Application Discontinuation
- 2003-06-16 AU AU2003241675A patent/AU2003241675A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4616083A (en) * | 1983-08-22 | 1986-10-07 | Shionogi & Co., Ltd. | Stable antibacterial lyophilizates |
US4822785A (en) * | 1986-07-10 | 1989-04-18 | Eisai Co., Ltd. | Cephalosporin injection |
JPH03264531A (ja) * | 1990-03-13 | 1991-11-25 | Mochida Pharmaceut Co Ltd | セファロスポリン凍結乾燥製剤 |
JPH0459730A (ja) * | 1990-06-26 | 1992-02-26 | Dai Ichi Seiyaku Co Ltd | セフェム系抗生物質含有凍結乾燥製剤 |
EP1134222A1 (en) * | 1998-11-27 | 2001-09-19 | Shionogi & Co., Ltd. | IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM |
WO2002088147A1 (fr) * | 2001-04-23 | 2002-11-07 | Shionogi & Co., Ltd. | Sulfate d'un compose cepheme |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1656930A1 (en) * | 2004-11-10 | 2006-05-17 | Basilea Pharmaceutica AG | Stabilized freeze-dried formulation for cephalosporin derivatives |
WO2006050631A1 (en) | 2004-11-10 | 2006-05-18 | Basilea Pharmaceutica Ag | Stabilized freeze-dried formulation for cephalosporin derivatives |
CN101056623B (zh) * | 2004-11-10 | 2011-04-06 | 巴斯利尔药物股份公司 | 稳定的头孢菌素衍生物冻干制剂 |
EP2210592A3 (en) * | 2004-11-10 | 2011-12-14 | Basilea Pharmaceutica AG | Stabilized Freeze-dried Formulation for Cephalosporin Derivatives |
EP2257159A2 (en) * | 2008-03-04 | 2010-12-08 | Elan Pharma International Limited | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
EP2257159A4 (en) * | 2008-03-04 | 2011-05-11 | Elan Pharma Int Ltd | STABLE LIQUID FORMULATIONS OF ANTI-INFECTIOUS AGENTS AND ADJUSTED DOSAGE REGIMES OF ANTI-INFECTIOUS AGENTS |
Also Published As
Publication number | Publication date |
---|---|
AU2003241675A1 (en) | 2004-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08500104A (ja) | 結晶質アミホスチン組成物及びその調製方法並びに使用 | |
JP6182262B2 (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
EP2094308B1 (en) | Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure | |
JP6832281B2 (ja) | バンコマイシンの水溶液製剤 | |
KR20130136466A (ko) | 카스포펀진 조성물 | |
ES2771227T3 (es) | Procedimiento de preparación de una composición farmacéutica liofilizada que contiene mitomicina C | |
CN110876259B (zh) | 注射用组合物 | |
CA1056729A (en) | Injectable amoxycillin composition | |
CA3040018A1 (en) | Pharmaceutical parenteral formulation containing carglumic acid | |
JP2023116657A (ja) | 安定な滅菌性且つ結晶性o-アセチルサリチル酸(アスピリン)のバイアル内堆積物 | |
JP3726255B2 (ja) | 安定な凍結乾燥済みチオテパ組成物 | |
WO2004000323A1 (ja) | セフェム化合物の注射用医薬組成物 | |
JP2010105965A (ja) | バンコマイシン製剤 | |
JP4594736B2 (ja) | 安定化されたアンスラサイクリン系化合物の凍結乾燥製剤 | |
WO2001047542A1 (fr) | Preparations de vancomycine | |
WO2020025069A1 (zh) | 一种水化环磷酰胺冻干组合物的方法及其产品 | |
TW200403064A (en) | Pharmaceutical composition for injection of cefem compound | |
WO2017198224A1 (zh) | 一种瑞马唑仑的药物组合物 | |
DK2436386T3 (en) | A stabilized and lyophilized formulation of the anthracycline compounds | |
CN111195235A (zh) | 一种水化环磷酰胺冻干组合物的方法及其产品 | |
US20200155579A1 (en) | Process for Hydrating Cyclophosphamide Freeze-Dried Composition and Product Thereof | |
JP2005200409A (ja) | 注射剤 | |
CN114929202A (zh) | 含有2-[(3-氨丙基)氨基]乙硫醇的冻干粉末及其用于制备热凝胶的用途 | |
CN110787137A (zh) | 环磷酰胺冻干组合物的水化方法及其产品 | |
CA2799489A1 (en) | An injectable dosage form of flupirtine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |